NEUROCRINE BIOSCIENCES INC (NBIX)
US64125C1099 - Common Stock
| MRQ (2023-9-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 293.70M | 262.90M | 340.80M | 187.10M | 112.30M | |||
| Marketable Securities | 801.40M | 726.40M | 370.50M | 613.90M | 558.20M | |||
| Receivables | 417.80M | 350.00M | 185.50M | 157.10M | 126.60M | |||
| Inventories | 28.80M | 35.10M | 30.50M | 28.00M | 17.30M | |||
| Other Current Assets | 108.20M | 79.10M | 45.50M | 30.10M | 16.60M | |||
| Total Current Assets | 1.65B | 1.45B | 972.80M | 1.02B | 831.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 149.60M | 145.60M | 155.80M | 127.40M | 116.30M | |||
| Investments And Advances | 587.50M | 401.50M | 624.40M | 265.30M | 355.50M | |||
| Intangibles | 34.90M | 37.20M | N/A | N/A | N/A | |||
| Other Non-Current Assets | 426.30M | 330.90M | 319.50M | 325.80M | 3.20M | |||
| Total Non-Current Assets | 1.20B | 915.20M | 1.10B | 718.50M | 475.00M | |||
| TOTAL ASSETS | 2.85B | 2.37B | 2.07B | 1.73B | 1.31B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 408.80M | |||
| Current Portion Of LT Debt. | 169.90M | 169.40M | N/A | N/A | N/A | |||
| Accrued Expenses | 125.90M | 129.30M | 99.50M | 81.40M | 72.70M | |||
| Accounts Payable | 394.90M | 235.70M | 142.80M | 97.60M | 46.20M | |||
| Other Current Liabilities | 900.00K | 3.30M | 3.50M | 7.50M | 37.50M | |||
| Total Current Liabilities | 691.60M | 537.70M | 245.80M | 186.50M | 565.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 335.10M | 317.90M | 0.00 | |||
| Other Non-Current Liabilities | 154.50M | 123.20M | 117.60M | 104.10M | 103.80M | |||
| Total Non-Current Liabilities | 154.50M | 123.20M | 452.70M | 422.00M | 103.80M | |||
| TOTAL LIABILITIES | 846.10M | 660.90M | 698.50M | 608.50M | 669.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -304.80M | -406.80M | -635.80M | -725.40M | -1.13B | |||
| Additional Paid In Capital | 2.31B | 2.12B | 2.01B | 1.85B | 1.77B | |||
| Common Shares | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | |||
| Other Shareholders' Equity | -1.70M | -7.90M | -1.70M | 1.80M | 1.40M | |||
| Shares Outstanding | 98.20M | 96.50M | 94.90M | 93.50M | 92.30M | |||
| Tangible Book Value per Share | 20.03 | 17.31 | 14.48 | 12.04 | 6.90 | |||
| Total Shareholders' Equity | 2.00B | 1.71B | 1.37B | 1.13B | 636.90M | |||
| TOTAL LIABILITIES AND EQUITY | 2.85B | 2.37B | 2.07B | 1.73B | 1.31B | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | 0.24 | 0.28 | N/A | |||
| Current Ratio | 2.39 | 2.70 | 3.96 | 5.45 | 1.47 | |||
| Return On Assets (ROA) | 6.71% | 6.52% | 4.32% | 23.48% | 2.83% | |||
| Return On Equity (ROE) | 9.54% | 9.05% | 6.52% | 36.17% | 5.81% | |||
| Return On Invested Capital (ROIC) | 12.95% | 10.99% | 9.13% | 16.99% | 15.83% | |||
| Return On Invested Capital Ex Cash (ROICexc) | 26.32% | 23.92% | 14.96% | 35.19% | 37.99% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 27.21% | 25.02% | 14.96% | 35.19% | 37.99% | |||
All data in USD